Pre-clinical evaluation of 2,3-dimercaptosuccinic acid as a radiation nephrotoxicity protective agent during radiopeptide therapy of neuroendocrine malignancy

Nuclear Medicine Communications

Volumn 28, Issue 4, 2007, Pages 261-266

  Moorin, Rachael E ^a   Meyrick, Danielle P ^b   Rose, Alison ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

Nephrotoxicity; Octreotate; Radiopeptide therapy; Somatostatin

Indexed keywords

OCTREOTATE[TYROSINE 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID LU 177]; PEPTIDE DERIVATIVE; SUCCIMER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG EFFICACY; MALE; NEPHROTOXICITY; NEUROENDOCRINE DISEASE; NONHUMAN; PENILE BLOOD VESSEL; RAT; STATISTICAL ANALYSIS; VEIN;

ANIMALS; BODY BURDEN; CHELATING AGENTS; DRUG EVALUATION, PRECLINICAL; KIDNEY; KIDNEY DISEASES; MALE; METABOLIC CLEARANCE RATE; NEUROECTODERMAL TUMORS; OCTREOTIDE; ORGAN SPECIFICITY; PEPTIDES; RADIATION DOSAGE; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; RADIOPHARMACEUTICALS; RATS; RATS, WISTAR; SUCCIMER; TREATMENT OUTCOME;

EID: 34247571070     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328014a11e     Document Type: Article

References (20)

1. de Jong M, Kwekkeboom D, Valkema R, Krenning EP. Radiolabelled peptides for tumour therapy: Current status and future directions. Eur J Nucl Med 2003; 30:463-469.
2. 111In-DTPA octreotide. J Nucl Med 2003; 44:98-104.
3. Warner RRP, O'Dorisio TM. Radiolabeled Peptides in diagnosis and tumor imaging: Clinical overview. Semin Nucl Med 2002; 32:79-83.
4. Rollerman EJ, Valkema R, de Jong M, Kooij PPM, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med 2003; 30:9-15.
5. 111In-DTPA octreotide: The Rotterdam experience. Semin Nucl Med 2002; 32:110-122.
6. De La Torre A, Belles M, Llobet JM, Mayayo E, Domingo JL. Comparison of the effectiveness of 2,3-dimercaptopropanol (BAL) and meso-2,3-dimercaptosuccinic acid (DMSA) as protective agents against mercuric chloride-induced nephrotoxicity in rats. Biological Trace Element Research 1998; 63:1-10.
7. Kostial K, Restek-Samarzja N, Blanusa M, Piasek M, Jones MM, Singh PK. Combined oral treatment with racemic and meso-2,3-dimercaptosuccinic acid for removal of mercury in rats. Pharmacol Toxicol 1997; 81:242-244.
8. Kostial K, Restek-Samarzja N, Blanusa M, Piasek M, Prester LJ, Jones MM, et al. Racemic-2,3-dimercaptosuccinic acid for inorganic mercury mobilization in rats. J Appl Toxicol 1996; 17:71-74.
9. Mishima K, Hidaka S, Takamura N, Shinozawa S. Protection against cis-diamminedichloroplatinum-induced nephrotoxicity by 2,3-dimercaptosuccinic acid in rats. Renal Failure 1999; 21:593-601.
10. Planas-Bohne F, Shand E, Taylor DM. The effects of dimercaptosuccinc acid and other chelating agents on the retention of platinum in the rat kidney after treatment with cisplatin. Cancer Chemother Pharmacol 1982; 9:120-121.
11. Jones MM, Singh PK, Kostial K, Blanusa M, Piasek M, Restek-Samarzja N. Comparative in vivo lead mobilization of mes- and rac-2,3-dimercaptosuccinic acids in albino Wistar rats. Pharmacol Toxicol 1997; 80:182-186.
12. Malvezzi CK, Moreira EG, Vassilieff I, Vassilieff VS, Cordellini S. Effect of L-arginine, dimercaptosuccinic Acid (DMSA) and the association of L-arginine and DMSA on tissue lead mobilization and blood pressure level in plumdism. Braz J Med Biol Res 2001; 34:1342-1346.
13. Zalups RK, Gelein RM, Cernichiari E. DMPS As a Rescue agent for the nephropathy induced by mercuric chloride. J Pharmacol Exp Ther 1991; 256:1-10.
14. Silbernagl S. The renal handling of amino acids and oligopeptides. Physiol Rev 1988; 68:912-986.
15. de Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom D, Breeman WAP, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 2002; 32:133-140.
16. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998; 25:201-212.
17. 90Y-DTPA-anti-CEA Mabs in nude mice bearing human colorectal cancer. J Nuc Med 2000; 41:337-344.
18. Provoost AP, Van Aken M. The effect of DMSA loading on the renal handling of technetium-99m in rats. Uremia Invest 1986; 9:147-150.
19. 99mTc-DMS complex in the rat kidney in vivo. Eur J Nucl Med 1981; 6:169-172.
20. 99mTc-DMSA in the rat. Eur J Nucl Med 1990; 16:29-34.